Filing Details

Accession Number:
0001104659-23-120804
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-22 17:00:50
Reporting Period:
2023-11-20
Accepted Time:
2023-11-22 17:00:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1722964 Y-Mabs Therapeutics Inc. YMAB Pharmaceutical Preparations (2834) 474619612
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753224 Thomas Gad C/O Y-Mabs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York NY 10169
Chief Business Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-11-20 75,000 $5.30 490,032 No 4 S Indirect By GAD Enterprises LLC
Common Stock Disposition 2023-11-21 75,000 $5.31 415,032 No 4 S Indirect By GAD Enterprises LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By GAD Enterprises LLC
No 4 S Indirect By GAD Enterprises LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 60,000 Indirect By children
Common Stock 90,500 Direct
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $5.2400 to $5.4800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed in multiple trades at prices ranging from $5.2300 to $5.4900. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
  4. Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
  5. Represents 50,000 shares of Common Stock owned by Reporting Person as well as 40,500 restricted stock units ("RSUs") granted to the Reporting Person on January 17, 2023 pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2024, January 17, 2025 and January 17, 2026 subject to the continuing employment of the Reporting Person on each vesting date.